Drug intelligence / Profile preview

203Pb-RMX-VHPIB

Development stage: Phase 1
Lead developer: Radiomedix
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous

Overview

203Pb-RMX-VHPIB is an investigational radiopharmaceutical diagnostic imaging agent developed by Radiomedix. It consists of a single-domain antibody (VHH or nanobody) targeting multiple members of the integrin family, specifically those containing the alpha-v subunit (such as αvβ3, αvβ5, and αvβ6), which are frequently overexpressed in various solid tumors including glioblastoma multiforme (GBM) and pancreatic ductal adenocarcinoma (PDAC). The nanobody is labeled with the radioisotope lead-203 (203Pb), which emits gamma radiation suitable for Single Photon Emission Computed Tomography (SPECT) imaging. This agent is designed to evaluate the biodistribution and radiation dosimetry of the targeting vector in patients, serving as a theranostic companion to the targeted alpha therapy 212Pb-RMX-VHPIB. By identifying tumors with high integrin expression, 203Pb-RMX-VHPIB facilitates patient selection and treatment planning for alpha-particle radioligand therapy.

Other names: 203Pb-RMX-VH-PIB injection

Targets

LDLR (Low-density lipoprotein receptor)

Beyond the preview

Go deeper on 203Pb-RMX-VHPIB.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 203Pb-RMX-VHPIB.

Explore the full profile